Live feed
·
INSIDERFilingvia Quantisnow
Windtree Therapeutics Inc. logo

Windtree Therapeutics (WINT) executive Fraser bought 1,497 shares for $2,650 at $1.77

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Craig Fraser (executive at Windtree Therapeutics Inc., WINT) reported that they bought 1,497 shares for $2,650 at $1.77 on Apr 26, 2023. After these transactions the filing shows 7,010 shares held directly.

Reporting person
Fraser Craig
Common stock and other non-derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Apr 26, 2023Open-market purchase (P)Common Stock+1,497$1.77$2,6507,010 direct

Holdings before and after

  • Common Stock: 5,513 to 7,010 direct

Other positions listed

  • Common Stock: 3 indirect, By Trust

Footnotes from the filing

  1. 1. Holding amount represents issuer's matching stock contribution pursuant to 401(k) plan.

Transaction codes in this filing

Open-market purchase:
Code P marks a purchase in the open market or a private deal. The insider paid for these securities.

FAQ

What did Fraser report in this WINT Form 4?

Craig Fraser (executive at Windtree Therapeutics Inc., WINT) reported that they bought 1,497 shares for $2,650 at $1.77 on Apr 26, 2023. After these transactions the filing shows 7,010 shares held directly.

How many WINT shares does Fraser hold after this filing?

The filing shows 7,010 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.

What does transaction code P mean on an SEC Form 4?

Code P marks a purchase in the open market or a private deal. The insider paid for these securities.

Historical context for WINT

Earlier insider filings at WINT

Quantisnow market dataNASDAQ
Windtree Therapeutics Inc. logo
WINT
Windtree Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for WINT

Follow WINT and get a push notification the moment its next story breaks.

Full WINT profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track WINT (Windtree Therapeutics Inc.) and more on Quantisnow.